6-[4-(2-Hydroxyethyl)piperazine-1-carbonyl]-2-methyl-2,3-dihydropyridazin-3-one

Catalog No. :
ACCRBX701
CAS No. :
1153231-27-6
Molecular Formula :
C12H18N4O3
Molecular Weight :
266.30

IUPAC Name:6-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2-methylpyridazin-3(2H)-one

6-[4-(2-Hydroxyethyl)piperazine-1-carbonyl]-2-methyl-2,3-dihydropyridazin-3-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$187.00Login to see priceInquiryInquiry
100mg98%$271.00Login to see priceInquiryInquiry
250mg98%$381.00Login to see priceInquiryInquiry
1g98%$788.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-[4-(2-Hydroxyethyl)piperazine-1-carbonyl]-2-methyl-2,3-dihydropyridazin-3-one
IUPAC Name6-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2-methylpyridazin-3(2H)-one
MDL No.MFCD12739808
Molecular FormulaC12H18N4O3
Molecular Weight266.30
SMILESO=C1C=CC(C(N2CCN(CCO)CC2)=O)=NN1C
InChI KeyNMIJOHIWZACUMG-UHFFFAOYSA-N
Synonym6-[4-(2-Hydroxyethyl)piperazine-1-carbonyl]-2-methyl-2,3-dihydropyridazin-3-one;6-([4-(2-Hydroxyethyl)piperazin-1-yl]carbonyl)-2-methyl-2,3-dihydropyridazin-3-one;3(2H)-Pyridazinone, 6-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-2-methyl-
CAS No.1153231-27-6

Synthetic Route by SureRoute

1. ACCRBX701 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHXMA731 route compound structure diagram
    ACHXMA731100047-66-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCRBX701 route product structure diagram
    ACCRBX7011153231-27-6
Inquiry

2. ACCRBX701 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCRBX701 route product structure diagram
    ACCRBX7011153231-27-6
Inquiry

Comments (0)